Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Konstantin Dragnev
Study ID
NCT00125359
Phase
PHASE2
Status
Completed

Conditions

  • Carcinoma, Non-small-cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer. Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Key Dates

First listed
Aug 1, 2005
Start date
Aug 31, 2005
Status verified
Dec 2018
Primary completion
Mar 31, 2014
Completion
Mar 31, 2014

Study Design

Enrollment
42 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    All eligible patients will receive continuous daily oral erlotinib 150mg with daily bexarotene oral capsules 400mg.

Primary Outcome Measure

Radiographic Response Rates [ Time Frame: Through study completion, an average of 1 year ]

Locations (2)

FacilityCityStateZIPSite coordinators
Norris Cotton Cancer CenterLebanonNew Hampshire03756-
Mount Sinai School of MedicineNew YorkNew York10029-

Find similar trials in Lebanon, NH

By research site
Norris Cotton Cancer Center· Lebanon, NHMount Sinai School of Medicine· New York, NY

Related Studies